KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation

Docetaxel is a first-line chemotherapy drug for castration-resistant prostate cancer (CRPC); yet, some CRPC patients develop docetaxel drug resistance. Cabazitaxel is approved in the post-docetaxel treatment setting. However, recent studies suggested cross-resistance between the development of drug...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Archives of biochemistry and biophysics 2023-03, Vol.737, p.109551-109551, Article 109551
Hauptverfasser:	Liu, Lina, Li, Mengyuan, Zhang, Junshuo, Xu, Dengfei, Guo, Yan, Zhang, Hui, Cang, Shundong
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Cabazitaxel Chemotherapy resistance Docetaxel Drug Resistance, Neoplasm - genetics Humans KIF14 Kinesins - metabolism Male Oncogene Proteins - metabolism Oncogene Proteins - therapeutic use Phosphorylation Prostate cancer Prostatic Neoplasms, Castration-Resistant - drug therapy Proto-Oncogene Proteins c-akt - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!